Relation’s Post

In a recent investor webinar, our Executive Director, Thomas Duthy provided an in-depth breakdown of our recent Phase I/II Clinical Trial Results for Rett Syndrome. Watch the update below as he explains the findings. You can watch the full investor webinar here:  https://lnkd.in/gWntFZps #RettSyndrome #Retts #Biotech #NTI #Neurotech

Next chapter for Sapreme!

Looking forward to seeing some known faces and meeting some new ones! Investing? How commercially viable is the science? What are the product development/CMC and regulatory risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! It has been great to work with innovators and the leaders to help them advance their asset and materialize the vision! Looking forward to connecting further to brainstorm solutions with you! #TexasLifeSciencesSummit #CPRIT #THBI

Come see us at #PsychCongress23 at booth 617. Come learn all about Castle Biosciences, Inc.'s PGx test IDgenetix. We can't wait to meet you! #PGxTesting #IDgenetix #Pharmacogenomics

Let the second Swiss Biotech Day begin! If you are at the conference and want to have a chat, let’s connect!

Thanks to my esteemed colleagues that joined me in a lively panel at the Sachs 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) to discuss keeping pace with market needs in oncology business development and licensing.    Super discussion moderated by Richard Ward and Michael R Huebner drawing on biotech and pharma players Astrid Maria Dahl, Göran Forsberg, Jesús Baena and Khatereh Ahmadi operating in a fast-changing world: emerging data and recent transactions in new modalities and therapies; forward-looking transaction strategies to meet future unmet needs as standard of care evolves; and crystal ball-gazing into emerging gamechangers like TLS (tertiary lymphoid structure) biology. Terrific exchange of ideas; can't wait to see the next set of transactions from this highly experienced group of deal-doers!

🧪 Target genes responsible for cancer, viral infections, and genetic disorders with our range of siRNA, miRNA, and RNAi vectors, as well as RNAi transfection reagents and more. Embrace the future with RNAi and witness the evolution of biotechnology in action. Save Now: 👉 https://lnkd.in/ep6JebuG #GeneTargeting #RNAi #Biotechnology #CancerResearch #ViralInfections #GeneticDisorders #InnovationInScience

AHEAD, in partnership with BD Biosciences, is gearing up to present a poster at the upcoming ESCCA (European Society for Clinical Cell Analysis) conference! This collaborative endeavor highlights the strength of partnerships in advancing clinical cell analysis. Our poster number is HEM-38. For friends and fellow flow cytometrists attending ESCCA, we invite you to visit our poster, where you can discover more about our collaboration with BD Biosciences and connect with our team. #aheadmedicine #bdbiosciences #ESCCA2023 #clinicalcellanalysis #flowcytometry #lymphomascreening

If you will be attending the International Complement Workshop (ICW) in Newcastle on August 31 to September 5 - do take the opportunity to meet with my colleagues from Svar. Apart from them being very nice people they are also highly competent in the Complement System and may offer valuable tips on how to study it. #svarlifescience #ICW #complement #complementsystem #FunctionalAndQuantitativeComplementELISAs

John Baust, President and Lead Scientists at CPSI Biotech, answers questions at the last CryoChats™ entitled 'Cryopreservation Benefits and Costs of DMSO' on April 17th, 2024. Question: "For post thaw assays, it is just enough to check for flow data and compare with pre thaw numbers or is it ok to expand these cells for few days, check for viability and also carry out flow data to be sure your cryo formulation had no impact on the cells." John also provided this link as a reference: https://lnkd.in/eZN6qBUY Join us for our next CryoChats™ entitled "Cryopreservation Clinical Risks" on June 12, 2024 at 1PM CDT. Register Here: https://lnkd.in/gUXVHa83 6/12 Assessing Operational Risk and Clinical Impact 7/31 Cryopreservation Scaling